Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 3/2008

01-05-2008

Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia

Authors: Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan Liu, Lan-Ping Xu, Yu-Hong Chen, Yu Wang, Wei Han, Huan Chen

Published in: Journal of Clinical Immunology | Issue 3/2008

Login to get access

Abstract

We evaluated the safety and efficacy of donor lymphocyte infusion (DLI) with granulocyte colony-stimulating factor priming and short-term immunosuppressive agents for prophylaxis of relapse in patients with advanced leukemia after human leukocyte antigen (HLA)-mismatched T cell-replete hematopoietic stem cell transplantation (HCT). Twenty-nine patients received prophylactic DLI at a median 75 (33–120) days after HCT. Acute graft-vs-host disease (GVHD) grades 3–4 occurred in six patients, and all cases were controlled. Eleven patients were alive and relapse-free with a probability of leukemia-free survival (LFS) of 37.3 ± 9.6% at 3 years. Chronic GVHD was associated with a lower relapse rate and higher probability of LFS. Prophylactic-modified DLI is feasible in patients with advanced leukemia to prevent relapse after HLA-mismatched HCT.
Literature
1.
Robak T, Wrzesien-Kus A. The search for optimal treatment in relapsed and refractory acute myeloid leukemia. Leuk Lymphoma 2002;43:281–91.PubMedCrossRef
2.
Michallet M, Thomas X, Vernant JP, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000;26:1157–63.PubMedCrossRef
3.
Slavin S, Naparstek E, Nagler A. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996;87:2195–204.PubMed
4.
Huang XJ, Guo NL, Ren HY, Xu LP, Chen H, Liu KY, et al. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chinese Med J 2003;116:736–41.
5.
Huang XJ, Liu DH, Xu LP, Chen H, Liu KY, Han W, et al. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006;20:365–8.PubMedCrossRef
6.
De Lima M, Bonamino M, Vasconcelos Z, et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001;27:73–8.PubMedCrossRef
7.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007;92:414–7.PubMedCrossRef
8.
Mengarelli A, Iori A, Guglielmi C, et al. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia. Haematologica 2002;87:52–8.PubMed
9.
10.
Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006;38:291–7.PubMedCrossRef
11.
Liu Y, Chen S, Yu H. Standardization and quality control in flow cytometric enumeration of CD34(+) cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2000;8:302–6.PubMed
12.
Flower ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disase. Hematol Oncol Clin North Am 1999;13:1091–112.CrossRef
13.
Keith MS. Graft-vs.-host disease. In: Thomas ED, Blume KG, Forman SJ, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation. 3rd ed. Malden, MA: Blackwell; 2004. p. 635–64.
14.
Singhal S, Powles R, Henslee-Downey PJ, et al. Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia. Bone Marrow Transplant 2002;29:291–5.PubMedCrossRef
15.
Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075–83.PubMed
16.
17.
Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J Clin Oncol 1992;10:1723–9.PubMed
18.
Christoph S, Michael S, Rainer S, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006;108:1092–9.CrossRef
19.
Alessandrino EP, Bernasconi P, Caldera D. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999;23:607–12.PubMedCrossRef
20.
Chen SH, Li X, Huang XJ. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004;79:178–84.PubMedCrossRef
21.
Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004;89:1517–24.
22.
Huang XJ, Chang YJ, Zhao XY. A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Haematologica 2005;90:715–6.
23.
Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transplant Immunol 2007;17:193–7.CrossRef
24.
Sohn SK, Jung JT, Kim DH, Lee NY, Seo KW, Chae YS, et al. Prophylactic growth factor-mobilized donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002;94:18–24.PubMedCrossRef
25.
Yanada M, Naoe T, Iida H. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005;36:867–72.PubMedCrossRef
26.
Ko BS, Tang JL, Tsai W. Philadelphia chromosome-positive acute lymphoblastic leukemia in Taiwan. Ann Hematol 2001;80:510–5.PubMedCrossRef
Metadata
Title
Modified Donor Lymphocyte Infusion after HLA-Mismatched/Haploidentical T Cell-replete Hematopoietic Stem Cell Transplantation for Prophylaxis of Relapse of Leukemia in Patients with Advanced Leukemia
Authors
Xiao-Jun Huang
Dai-Hong Liu
Kai-Yan Liu
Lan-Ping Xu
Yu-Hong Chen
Yu Wang
Wei Han
Huan Chen
Publication date
01-05-2008
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2008
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-007-9166-z

Other articles of this Issue 3/2008

Journal of Clinical Immunology 3/2008 Go to the issue

OriginalPaper

Significance of Transporter Associated with Antigen Processing 2 (TAP2) Gene Polymorphisms in Susceptibility to Dengue Viral Infection

OriginalPaper

Interleukin-10 and Tumor Necrosis Factor-α Gene Polymorphisms in Tuberculosis

OriginalPaper

Prospective Study on CVID Patients with Adverse Reactions to Intravenous or Subcutaneous IgG Administration

OriginalPaper

CD72 Polymorphism Associated with Child-Onset of Idiopathic Thrombocytopenic Purpura in Chinese Patients

OriginalPaper

Interferon-α Induces Up-regulation and Nuclear Translocation of the Ro52 Autoantigen as Detected by a Panel of Novel Ro52-specific Monoclonal Antibodies

OriginalPaper

FcγRI-Mediated Activation of Human Mast Cells Promotes Survival and Induction of the Pro-survival Gene Bfl-1
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits